Drug Sponsors

LifeNet Health to create 321 new jobs in Virginia

Friday, August 18, 2017

LifeNet Health, a global regenerative medicine company, has announced that it will invest $12.25 million to expand its global headquarters operation in the City of Virginia Beach. The non-profit will add a 100,000-square-foot warehouse, 20,000 square feet of office space, and an 18,000-square-foot R&D and production facility across three campuses. Virginia successfully competed against Florida, North Carolina, and Washington for the project, which will create 321 new jobs.

[Read More]

Walgreens launches Center for Health & Wellbeing Research

Thursday, August 17, 2017

Walgreens announced the launch of its Center for Health & Wellbeing Research, a website that features more than 50 Walgreens outcomes studies completed over the past six years. Areas of research include access to care and patient experience, adherence and clinical outcomes, digital health and member engagement, health care costs, HIV and specialty pharmacy, vaccinations and more.

[Read More]

Affinity Bio Partners launches Pennsylvania cannabis biotech company

Tuesday, August 15, 2017

Affinity Bio Partners CEO Christina DiArcangelo Puller announced that she is adding another organization to the Affinity family of organizations by launching Affinity BioCeuticals, a “first of its kind” Cannabis Biotech Pennsylvania corporation. Affinity BioCeuticals is a Neutraceutical company focused on research and development of cannabinoid based therapies. The emergence of more and more indications where cannabinoid based treatment may be impactful to patient’s lives will be the primary focus for Affinity BioCeuticals. 

[Read More]

SK Capital to acquire Perrigo’s Active Pharmaceutical Ingredients Business

Tuesday, August 15, 2017

SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, has signed a definitive agreement to acquire Perrigo API, Perrigo’s active pharmaceutical ingredients (API) business. As part of the transaction, the parties have agreed to enter into a long-term supply agreement for Perrigo API to supply multiple existing commercial and pipeline APIs to Perrigo. The transaction is expected to close during Q4 2017, before which a new trade name will be selected and announced for the Business.

[Read More]

Pfizer expands in North Carolina

Tuesday, August 15, 2017

Pfizer, a biopharmaceutical company, has selected Lee County for a new expansion of its manufacturing facilities as the company prepares to produce new gene therapy medicines. Governor Roy Cooper announced the company plans to invest $100 million in its Sanford facilities, creating 40 jobs and building upon a technology first developed at the University of North Carolina at Chapel Hill.

[Read More]

NantHealth restructures, to cut 300 positions

Monday, August 14, 2017

NantHealth, a next-generation, evidence-based, personalized healthcare company, has taken a series of methodically analyzed actions, planned over the past nine months post initial public offering (IPO), to focus the business on its core competencies of artificial intelligence and be a leading cancer company.

[Read More]

Cempra, Melinta merge to form commercial-stage anti-infectives company

Wednesday, August 9, 2017

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases, and Melinta Therapeutics, a privately held company focused on discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, have announced that the companies have entered into a definitive agreement under which Melinta will merge with a subsidiary of Cempra. The merger is expected to create a company committed to discovering, developing and commercializing important anti-infective therapies for patients and physicians in areas of significant unmet need.

[Read More]

Bristol-Myers Squibb to acquire IFM Therapeutics

Wednesday, August 9, 2017

Bristol-Myers Squibb and IFM Therapeutics (IFM) announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

[Read More]

Co-Diagnostics, Synbiotics launch joint venture CoSara Diagnostics in India

Tuesday, July 25, 2017

Co-Diagnostics, a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced the recent incorporation of CoSara Diagnostics, a Joint Venture for manufacturing with Synbiotics. Synbiotics is a group company of Asence, a U.S. incorporated company specializing in supplying pharmaceutical products to international markets.

[Read More]